Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
PTLA's Cash to Debt is ranked higher than
86% of the 1276 Companies
in the Global Biotechnology industry.

( Industry Median: 72.05 vs. PTLA: No Debt )
PTLA' s 10-Year Cash to Debt Range
Min: No Debt   Max: No Debt
Current: No Debt

Equity to Asset 0.84
PTLA's Equity to Asset is ranked higher than
87% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 0.66 vs. PTLA: 0.84 )
PTLA' s 10-Year Equity to Asset Range
Min: -1.31   Max: 0.91
Current: 0.84

-1.31
0.91
Interest Coverage No Debt
PTLA's Interest Coverage is ranked higher than
100% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. PTLA: No Debt )
PTLA' s 10-Year Interest Coverage Range
Min: 946.14   Max: 9999.99
Current: No Debt

946.14
9999.99
F-Score: 3
Z-Score: 14.83
M-Score: -3.69
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -1429.11
PTLA's Operating margin (%) is ranked higher than
57% of the 1044 Companies
in the Global Biotechnology industry.

( Industry Median: -85.54 vs. PTLA: -1429.11 )
PTLA' s 10-Year Operating margin (%) Range
Min: -1429.26   Max: 25.46
Current: -1429.11

-1429.26
25.46
Net-margin (%) -1424.53
PTLA's Net-margin (%) is ranked higher than
57% of the 1044 Companies
in the Global Biotechnology industry.

( Industry Median: -80.82 vs. PTLA: -1424.53 )
PTLA' s 10-Year Net-margin (%) Range
Min: -1424.68   Max: 25.61
Current: -1424.53

-1424.68
25.61
ROE (%) -50.25
PTLA's ROE (%) is ranked higher than
68% of the 1162 Companies
in the Global Biotechnology industry.

( Industry Median: -32.57 vs. PTLA: -50.25 )
PTLA' s 10-Year ROE (%) Range
Min: -159.12   Max: -42.58
Current: -50.25

-159.12
-42.58
ROA (%) -41.91
PTLA's ROA (%) is ranked higher than
67% of the 1282 Companies
in the Global Biotechnology industry.

( Industry Median: -26.11 vs. PTLA: -41.91 )
PTLA' s 10-Year ROA (%) Range
Min: -36.95   Max: 20.67
Current: -41.91

-36.95
20.67
ROC (Joel Greenblatt) (%) -5032.41
PTLA's ROC (Joel Greenblatt) (%) is ranked higher than
58% of the 1245 Companies
in the Global Biotechnology industry.

( Industry Median: -373.92 vs. PTLA: -5032.41 )
PTLA' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -5117.78   Max: 1022.07
Current: -5032.41

-5117.78
1022.07
» PTLA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

PTLA Guru Trades in

PTLA Guru Trades in

Q3 2014

PTLA Guru Trades in Q3 2014

Steven Cohen 160,000 sh (New)
» More
Q4 2014

PTLA Guru Trades in Q4 2014

Steven Cohen Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with PTLA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 5.40
PTLA's P/B is ranked higher than
70% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 6.46 vs. PTLA: 5.40 )
PTLA' s 10-Year P/B Range
Min: 3.07   Max: 5.83
Current: 5.4

3.07
5.83
P/S 170.30
PTLA's P/S is ranked higher than
54% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 31.20 vs. PTLA: 170.30 )
PTLA' s 10-Year P/S Range
Min: 5.28   Max: 181.39
Current: 170.3

5.28
181.39
EV-to-EBIT -11.51
PTLA's EV-to-EBIT is ranked higher than
80% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. PTLA: -11.51 )
PTLA' s 10-Year EV-to-EBIT Range
Min: -12.4   Max: -1.3
Current: -11.51

-12.4
-1.3
Current Ratio 7.66
PTLA's Current Ratio is ranked higher than
83% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.61 vs. PTLA: 7.66 )
PTLA' s 10-Year Current Ratio Range
Min: 7.17   Max: 10.67
Current: 7.66

7.17
10.67
Quick Ratio 7.66
PTLA's Quick Ratio is ranked higher than
84% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.33 vs. PTLA: 7.66 )
PTLA' s 10-Year Quick Ratio Range
Min: 7.17   Max: 10.67
Current: 7.66

7.17
10.67
Days Sales Outstanding 2.16
PTLA's Days Sales Outstanding is ranked higher than
99% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 111.38 vs. PTLA: 2.16 )
PTLA' s 10-Year Days Sales Outstanding Range
Min: 2.16   Max: 10.71
Current: 2.16

2.16
10.71

Valuation & Return

vs
industry
vs
history
Price/Net Cash 7.70
PTLA's Price/Net Cash is ranked higher than
84% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 87.00 vs. PTLA: 7.70 )
PTLA' s 10-Year Price/Net Cash Range
Min: 4.4   Max: 5.74
Current: 7.7

4.4
5.74
Price/Net Current Asset Value 7.70
PTLA's Price/Net Current Asset Value is ranked higher than
82% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 28.08 vs. PTLA: 7.70 )
PTLA' s 10-Year Price/Net Current Asset Value Range
Min: 4.33   Max: 5.61
Current: 7.7

4.33
5.61
Price/Tangible Book 5.30
PTLA's Price/Tangible Book is ranked higher than
78% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 9.40 vs. PTLA: 5.30 )
PTLA' s 10-Year Price/Tangible Book Range
Min: 3.56   Max: 5.01
Current: 5.3

3.56
5.01
Price/Median PS Value 2.50
PTLA's Price/Median PS Value is ranked higher than
73% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 2.90 vs. PTLA: 2.50 )
PTLA' s 10-Year Price/Median PS Value Range
Min: 0.15   Max: 1.83
Current: 2.5

0.15
1.83
Earnings Yield (Greenblatt) -9.00
PTLA's Earnings Yield (Greenblatt) is ranked higher than
65% of the 1260 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. PTLA: -9.00 )
PTLA' s 10-Year Earnings Yield (Greenblatt) Range
Min: -12.2   Max: 0
Current: -9

-12.2
0

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:0PP.Germany,
Portola Pharmaceuticals Inc was incorporated in Delaware in September 2003. The Company is a biopharmaceutical company engaged in the development and commercialization of novel therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients who currently have limited or no approved treatment options. Its two programs address significant unmet medical needs in the areas of thrombosis or blood clots. Its compound Betrixaban is a novel oral once-daily inhibitor of Factor Xa in Phase 3 development for extended duration prophylaxis, or preventive treatment, of a form of thrombosis known as venous thromboembolism, or VTE, in acute medically ill patients. The Company's current product candidates in development includes: Betrixaban, PRT4445, PRT2070, and PRT2607. Betrixaban is a novel oral once-daily inhibitor of Factor Xa in development for extended duration VTE prophylaxis in acute medically ill patients for up to 35 days. PRT4445 is a recombinant protein designed to reverse the anticoagulant activity in patients treated with a Factor Xa inhibitor who suffer an uncontrolled bleeding episode or undergo emergency surgery. PRT2070 is an orally available, potent inhibitor of Syk and JAK. PRT2607 is an orally available, potent and selective inhibitor of Syk. The Company faces competition from large and small pharmaceutical and biotechnology companies, specialty pharmaceutical companies, generic drug companies, academic institutions, government agencies and research institutions and others.
» More Articles for PTLA

Headlines

Articles On GuruFocus.com
Paulson Bets Again On Mallinckrodt Aug 07 2014 

More From Other Websites
Weakness Seen in Portola Pharmaceuticals (PTLA): Stock Falls 5.7% - Tale of the Tape Mar 11 2015
PORTOLA PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Mar 11 2015
PORTOLA PHARMACEUTICALS INC Financials Mar 10 2015
Portola Pharmaceuticals Announces Proposed Offering of Common Stock Mar 10 2015
Portola Announces Pricing of Public Offering of Common Stock Mar 10 2015
Portola Announces Pricing of Public Offering of Common Stock Mar 10 2015
Portola Pharmaceuticals Announces Proposed Offering of Common Stock Mar 09 2015
Portola Pharmaceuticals to Present at the Cowen and Company 35th Annual Health Care Conference Mar 03 2015
Portola Announces Full Results From Positive Phase 3 ANNEXA(TM)-R Study Demonstrating That Andexanet... Mar 03 2015
Portola Pharmaceuticals Reports Fourth Quarter and Year-End 2014 Financial Results and Provides... Mar 03 2015
Portola Pharmaceuticals Receives FDA Orphan Drug Designation for Andexanet Alfa, Its... Mar 02 2015
Portola Pharmaceuticals posts 4Q loss Mar 02 2015
Portola Pharmaceuticals posts 4Q loss Mar 02 2015
Portola Pharmaceuticals Inc Earnings Call scheduled for 8:30 am ET today Mar 02 2015
PORTOLA PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Mar 02 2015
Portola Announces Full Results From Positive Phase 3 ANNEXA(TM)-R Study Demonstrating That Andexanet... Mar 02 2015
Portola Pharmaceuticals Reports Fourth Quarter and Year-End 2014 Financial Results and Provides... Mar 02 2015
Q4 2014 Portola Pharmaceuticals Inc Earnings Release - Before Market Open Mar 02 2015
Portola Pharmaceuticals Receives FDA Orphan Drug Designation for Andexanet Alfa, Its... Feb 26 2015
Portola Pharmaceuticals to Present at the Cowen and Company 35th Annual Health Care Conference Feb 25 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK